Inovio Pharmaceuticals Company Leadership
| INO Stock | USD 4.19 0.18 4.49% |
Inovio Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Inovio Pharmaceuticals suggests that virtually all insiders are panicking. Inovio Pharmaceuticals employs about 127 people. The company is managed by 14 executives with a total tenure of roughly 33 years, averaging almost 2.0 years of service per executive, having 9.07 employees per reported executive.
| Jacqueline Shea CEO President CEO |
Inovio Pharmaceuticals' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2023-03-13 | David B Weiner | Disposed 40 @ 165.6 | View | ||
| 2023-02-27 | David B Weiner | Disposed 81 @ 184.32 | View | ||
| 2022-08-11 | David B Weiner | Disposed 82 @ 383.04 | View | ||
| 2022-07-20 | Simon X Benito | Disposed 13 @ 324 | View | ||
| 2022-03-16 | Simon X Benito | Disposed 13 @ 455.04 | View | ||
| 2022-03-14 | David B Weiner | Disposed 28 @ 460.8 | View | ||
| 2022-01-19 | Simon X Benito | Disposed 13 @ 614.88 | View |
Monitoring Inovio Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Inovio |
Inovio Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Inovio Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Inovio will maintain a workforce of about 130 employees by December 2024.Inovio Pharmaceuticals Management Team Effectiveness
The company has Return on Asset of (0.3991) % which means that on every $100 spent on assets, it lost $0.3991. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.9142) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharmaceuticals' management efficiency ratios could be used to measure how well Inovio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -1.09. At this time, Inovio Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 29th of November 2024, Other Current Assets is likely to grow to about 6.9 M, while Total Assets are likely to drop about 131.2 M.As of the 29th of November 2024, Common Stock Shares Outstanding is likely to grow to about 28 M, though Net Loss is likely to grow to (239.2 M).
Inovio Pharmaceuticals Workforce Comparison
Inovio Pharmaceuticals is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,859. Inovio Pharmaceuticals holds roughly 127 in number of employees claiming about 7% of equities under Health Care industry.
Inovio Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inovio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inovio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Inovio Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 1.5556 | 28 | 18 | 89,840 | 68,627 |
| 2024-03-01 | 1.1818 | 13 | 11 | 209,567 | 22,460 |
| 2023-06-01 | 2.3333 | 28 | 12 | 1,741,190 | 280,404 |
| 2023-03-01 | 0.7917 | 19 | 24 | 1,944,884 | 657,466 |
| 2022-09-01 | 0.3333 | 2 | 6 | 13,875 | 41,625 |
| 2022-06-01 | 2.5556 | 23 | 9 | 898,400 | 132,600 |
| 2022-03-01 | 0.6842 | 26 | 38 | 2,818,029 | 855,895 |
| 2021-06-01 | 1.15 | 23 | 20 | 450,450 | 229,771 |
| 2021-03-01 | 0.6731 | 35 | 52 | 2,000,950 | 1,470,455 |
| 2020-12-01 | 0.5 | 4 | 8 | 41,590 | 108,556 |
| 2020-09-01 | 0.25 | 1 | 4 | 35,000 | 189,467 |
| 2020-06-01 | 1.7273 | 19 | 11 | 188,828 | 122,449 |
| 2020-03-01 | 0.8571 | 24 | 28 | 1,575,391 | 628,437 |
| 2019-12-01 | 1.0 | 1 | 1 | 4,090 | 4,090 |
| 2019-09-01 | 1.0 | 1 | 1 | 4,500 | 16,352 |
| 2019-06-01 | 1.6667 | 20 | 12 | 204,441 | 2,407,171 |
| 2019-03-01 | 0.9643 | 27 | 28 | 1,644,936 | 795,679 |
| 2018-12-01 | 0.75 | 3 | 4 | 39,091 | 49,092 |
| 2018-09-01 | 0.4 | 2 | 5 | 64,060 | 148,120 |
| 2018-06-01 | 1.6 | 24 | 15 | 429,037 | 514,993 |
| 2018-03-01 | 0.9286 | 26 | 28 | 1,589,907 | 467,972 |
| 2017-09-01 | 1.0 | 1 | 1 | 61,325 | 61,325 |
| 2017-06-01 | 2.3333 | 21 | 9 | 224,516 | 102,088 |
| 2017-03-01 | 1.12 | 28 | 25 | 1,407,945 | 594,897 |
| 2016-09-01 | 0.5 | 1 | 2 | 33,116 | 54,916 |
| 2016-06-01 | 2.4167 | 29 | 12 | 523,284 | 431,098 |
| 2016-03-01 | 1.7778 | 16 | 9 | 901,836 | 52,030 |
| 2015-09-01 | 3.0 | 3 | 1 | 316,625 | 306,625 |
| 2015-03-01 | 9.0 | 9 | 1 | 398,750 | 85,000 |
| 2014-06-01 | 11.0 | 11 | 1 | 1,080,000 | 18,750 |
| 2014-03-01 | 4.0 | 4 | 1 | 750,000 | 18,750 |
| 2013-03-01 | 5.5 | 11 | 2 | 1,295,000 | 173,750 |
| 2012-03-01 | 3.6667 | 11 | 3 | 1,251,800 | 159,300 |
| 2011-12-01 | 0.1667 | 3 | 18 | 37,150 | 4,309,850 |
| 2011-09-01 | 1.625 | 13 | 8 | 303,567 | 1,437,300 |
| 2011-06-01 | 1.2857 | 9 | 7 | 342,800 | 4,800,000 |
| 2011-03-01 | 0.5 | 3 | 6 | 520,000 | 1,012,500 |
| 2009-12-01 | 1.3333 | 8 | 6 | 1,366,688 | 1,216,688 |
| 2009-09-01 | 5.0 | 10 | 2 | 1,070,000 | 135,000 |
| 2009-06-01 | 0.125 | 1 | 8 | 30,000 | 196,240 |
| 2008-12-01 | 2.5 | 5 | 2 | 260,000 | 1,226,500 |
| 2008-09-01 | 0.6667 | 4 | 6 | 255,000 | 289,454 |
| 2008-03-01 | 0.6667 | 6 | 9 | 280,000 | 137,279 |
| 2007-06-01 | 6.0 | 6 | 1 | 165,000 | 0.00 |
| 2007-03-01 | 3.0 | 6 | 2 | 700,000 | 82,850 |
| 2006-12-01 | 0.7 | 7 | 10 | 47,500 | 283,210 |
| 2004-12-01 | 0.7 | 7 | 10 | 50,000 | 695,850 |
| 2004-09-01 | 27.0 | 27 | 1 | 110,309 | 70,000 |
| 2004-06-01 | 2.5 | 5 | 2 | 175,000 | 150,000 |
| 2003-12-01 | 0.6 | 3 | 5 | 450,000 | 316,240 |
| 2003-09-01 | 10.0 | 10 | 1 | 1,026,532 | 25,532 |
Inovio Pharmaceuticals Notable Stakeholders
An Inovio Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Inovio Pharmaceuticals often face trade-offs trying to please all of them. Inovio Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Inovio Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jacqueline Shea | President CEO | Profile | |
| Asli Gevgilili | Chief Officer | Profile | |
| Jeffrey Skolnik | Senior Development | Profile | |
| Robert Juba | Senior Management | Profile | |
| E MBA | Senior Assurance | Profile | |
| MBA MA | Senior Development | Profile | |
| Ben Matone | Director Relations | Profile | |
| Laurent Humeau | Chief Scientific Officer | Profile | |
| Thomas Hong | Manager Relations | Profile | |
| Daniel Jordan | VP Operations | Profile | |
| Robert JD | General Officer | Profile | |
| PE MBA | Senior Development | Profile | |
| David MD | Senior Development | Profile | |
| Peter Kies | Chief Officer | Profile |
About Inovio Pharmaceuticals Management Performance
The success or failure of an entity such as Inovio Pharmaceuticals often depends on how effective the management is. Inovio Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inovio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inovio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (1.04) | (1.09) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.15) | (1.21) |
Inovio Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Inovio Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Inovio Pharmaceuticals within its industry.Inovio Pharmaceuticals Manpower Efficiency
Return on Inovio Pharmaceuticals Manpower
| Revenue Per Employee | 6.6K | |
| Revenue Per Executive | 59.4K | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 9.7M | |
| Working Capital Per Employee | 870.4K | |
| Working Capital Per Executive | 7.9M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.